These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
191 related items for PubMed ID: 8174800
1. Biologicals: an attempt at classification and its implication for the viral safety of products. Horaud F. Dev Biol Stand; 1993; 81():17-24. PubMed ID: 8174800 [No Abstract] [Full Text] [Related]
2. Viral safety of biological products and the concept of validation. Horaud F. Dev Biol Stand; 1996; 88():19-24. PubMed ID: 9119135 [No Abstract] [Full Text] [Related]
3. Introductory remarks: viral safety of biologicals. Horaud F. Dev Biol Stand; 1991; 75():3-7. PubMed ID: 1794630 [No Abstract] [Full Text] [Related]
4. Viral safety of recombinant factor IX. Adamson S, Charlebois T, O'Connell B, Foster W. Semin Hematol; 1998 Apr; 35(2 Suppl 2):22-7. PubMed ID: 9565163 [Abstract] [Full Text] [Related]
5. Surveillance for transfusion-transmitted viral infections in the United States. Chamberland ME. Biologicals; 1998 Jun; 26(2):85-8. PubMed ID: 9811510 [Abstract] [Full Text] [Related]
6. Safety of biological products prepared from mammalian cell culture. Bovine spongiform encephalopathy and other non-viral transmissible agents. Dev Biol Stand; 1998 Jun; 93():133-4. PubMed ID: 9737391 [No Abstract] [Full Text] [Related]
7. The clearance of viruses and transmissible spongiform encephalopathy agents from biologicals. Farshid M, Taffs RE, Scott D, Asher DM, Brorson K. Curr Opin Biotechnol; 2005 Oct; 16(5):561-7. PubMed ID: 16095899 [Abstract] [Full Text] [Related]
9. Avoiding viral contamination in biotechnological and pharmaceutical processes. Henzler HJ, Kaiser K. Nat Biotechnol; 1998 Nov; 16(11):1077-9. PubMed ID: 9831040 [No Abstract] [Full Text] [Related]
10. Viral safety of biological products in WHO policy. Grachev VP. Dev Biol Stand; 1991 Nov; 75():241-6. PubMed ID: 1794628 [Abstract] [Full Text] [Related]
11. Bad blood and biologicals: the need for new radiopharmaceutical source materials. Perkins AC, Frier M. Nucl Med Commun; 1999 Jan; 20(1):1-3. PubMed ID: 9949406 [No Abstract] [Full Text] [Related]
12. Safety of biological products prepared from mammalian cell culture. Host-cell proteins. Dev Biol Stand; 1998 Jan; 93():139-40. PubMed ID: 9737394 [No Abstract] [Full Text] [Related]
13. Transmissible spongiform encephalopathies and the safety of naturally-derived biologicals. Di Martino A. Biologicals; 1993 Mar; 21(1):61-6. PubMed ID: 8217119 [Abstract] [Full Text] [Related]
14. Process evaluation for biopharmaceuticals: what is appropriate in process evaluation? Lubiniecki AS, McAllister PR, Smith TM, Shadle PJ. Dev Biol Stand; 1996 Mar; 88():309-15. PubMed ID: 9119154 [No Abstract] [Full Text] [Related]
15. [Iatrogenic Creutzfeld-Jakob disease. Significance of cases observed after extracted growth hormone treatment]. Billette de Villemeur T. Rev Neurol (Paris); 1998 Oct; 154(10):651-2. PubMed ID: 9846334 [No Abstract] [Full Text] [Related]
16. Relationship between nature and source of risk and process validation. Berthold W, Werz W, Walter JK. Dev Biol Stand; 1996 Oct; 88():59-71. PubMed ID: 9119164 [No Abstract] [Full Text] [Related]
17. Safety of biological products prepared from mammalian cell culture. DNA. Dev Biol Stand; 1998 Oct; 93():136-8. PubMed ID: 9737393 [No Abstract] [Full Text] [Related]
18. Report of the Committee on Infectious Diseases. J Clin Neurophysiol; 1994 Jan; 11(1):128-32. PubMed ID: 8195418 [No Abstract] [Full Text] [Related]